HALOZYME THERAPEUTICS INC (HALO)
US40637H1095 - Common Stock
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier.
Beam Therapeutics Stock Earns RS Rating Jump To 85
On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85.
Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective.
There are signs that NASDAQ:HALO may be ready to breakout.
3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
These biotech stocks have promising outlooks that will bring major fortune to investors. Buy before it is too late.
NASDAQ:HALO is showing good growth, while it is not too expensive.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is not too expensive for the growth it is showing.
Biotech Arvinas Stock Earns 82 RS Rating
The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82.
Denali Therapeutics Stock Gets Technical Rating Upgrade
Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
3 Biotech Stocks to Buy Now: Q3 Edition
Biotech stocks to buy can be a strong portfolio addition due to their capability for rapid growth within an evolving industry.
NASDAQ:HALO qualifies as a high growth stock and is consolidating.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): a strong growth stock preparing for the next leg up?.
NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is probably undervalued for the fundamentals it is displaying.
NASDAQ:HALO Shows Potential for a Breakout.
Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective.
3 Highly Rated Biotech Stocks for Your July Buy List
Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street.
3 Breakout Biotech Stocks on Track to Double by 2032
The tech sector has been at the forefront of the market rally in 2024. Consider these breakout biotech stocks as a great way to diversify.
UroGen Pharma Stock Earns 91 RS Rating
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier.
Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received European Commission (EC) marketing authorization of...
Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
Sarepta Therapeutics had its Relative Strength (RS) Rating upgraded to 95 Monday, up from 68 a day earlier.
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received U.S. Food and Drug Administration (FDA) approval...
Halozyme Therapeutics Larger Than S&P 500 Component Paramount Global
Arcellx Stock Earns Relative Strength Rating Upgrade
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83.
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level.
The 3 Best Healthcare Stocks to Buy in June 2024
Aging populations and changing lifestyles mean healthcare is a secular story that these best healthcare stocks to buy will capitalize on.
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas.
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90.
Krystal Biotech Stock Sees RS Rating Jump To 91
On Tuesday, Krystal Biotech stock cleared a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88.
Halozyme Therapeutics Scores RS Rating Jump To 91
On Friday, Halozyme Therapeutics stock earned an upgrade to its Relative Strength (RS) Rating, from 80 to 91.
Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that the Company is raising its full year 2024 financial guidance and...
Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20...
Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will...